Favorable outcomes with tumor burden reduction following administration of hypomethylating agents before allogeneic hematopoietic cell transplantation in patients with higher-risk myelodysplastic syndrome

ConclusionTo predict the clinical outcomes of patients with higher-risk MDS, the optimal time for tumor burden evaluation is prior to follow-up rather than at the time of initial diagnosis. Patients with lower IPSS risk groups after HMA treatment or early HCT had favorable OS.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research